Organisation paid for research Program year 2025 Source: CMS Open Payments

Xcancer Research Network LLC

Neither a doctor nor a teaching hospital

Research payments

$141,682

7 payments

Through program year 2025, Xcancer Research Network LLC is reported as receiving $141,682 in research payments, across 7 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$115,350	5
2024	Research	$26,332	2

Breakdown

Who paid Research payments · program years 2024–2025

Janssen Research & Development, LLC $115,350 5 payments
Exelixis Inc. $26,332 2 payments

Studies the money was for Research payments · program years 2024–2025

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer $62,934 3 payments
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer $52,416 2 payments
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors $26,332 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.